An observational study in Crohn Disease and Arthritis, Rheumatoid, sponsored by Janssen Inc.. Completed at 2 sites in Canada. Per ClinicalTrials.gov, last updated 2013-01-15.
Sponsored by Janssen Inc. · Observational
Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 1,630 is above the median of 155 across 1,057 observational studies indexed under Arthritis.
Browse Arthritis studies →Janssen Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The data captured and reported in this registry will reflect a "real world" approach to the treatment of Rheumatoid Arthritis and Crohn's Disease with infliximab.
Exclusion Criteria:
Type and frequency of infusion reactions
Time frame: Up to 7 years
Pre-infusion treatments and efficacy
Time frame: Up to 7 years
Infusion reaction management approaches
Time frame: Up to 7 years
The number of subjects with adverse events
Time frame: Up to 7 years
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Inc.